Efficacy of atosiban for threatened preterm birth
Objective. To evaluate the efficacy of atosiban in the treatment of threatened preterm birth.Baev O.R., Vasilchenko O.N., Karapetyan A.O., Tetruashvili N.K., Khodzhaeva Z.S.
Subjects and methods. In 2014 to 2015, fifty-seven patients with threatened preterm birth at 24 to 34 weeks’ gestation were examined and treated with atosiban. The duration of pregnancy at admission ranged from 28 to 33 weeks and averaged 31.02±1.44 weeks. There were 45 women with singleton pregnancies, 45 and 1 with twin and triplet pregnancies, respectively. The average duration of pregnancy was 216.49 days in singleton pregnancies and 211.17 days in multiple ones.
Results. The cervical length measured by ultrasound cervicometry was 7 to 28 mm (2.36±0.49 mm). Cervical ripening assessed using the modified Bishop scores was 4 to 9 (5.32±0.86).
The vast majority of patients reported improvements within the first 3 hours (2.25±0.63) after treatment initiation. According to the self-assessment scale, 16 (28.1%) patients noted an insignificant improvement at 3 hours after start of therapy; 37 (64.9%) patients observed a significant improvement; all the pregnant women had this at 24 hours.
The analysis of outcomes showed that pregnancy could be prolonged for more than 48 hours in 96.5% of cases: for ≥ 7 and ≥ 14 days from the start of treatment in 19.3 and 77.2% of cases, respectively. Delivery occurred at term in 33.3% of cases.
Conclusion. Thus, atosiban has been proven to be an effective tocolytic agent in treating early threatened preterm labor during both singleton and multiple pregnancies.
Keywords
threatening preterm labor
tocolytics
atosiban
Supplementary Materials
- Fig. 1. Cardiotocogram. The arrow indicates the time of loading dose of atosiban, after which the fetal heart rate quickly normalized
- Fig. 2. Frequency and duration of pregnancy prolongation
References
1. Menon R. Preterm birth: a global burden on maternal and child health. Pathog. Glob. Health. 2012; 106(3): 139-40.
2. Nour N.M. Premature delivery and the millennium development goal. Rev. Obstet. Gynecol. 2012; 5(2): 100-5.
3. Ходжаева З.С., Федотовская О.И., Холин А.М. Медикаментозная терапия угрожающих преждевременных родов. Акушерство и гинекология. 2013; 5: 17-22. [Khodzhaeva Z.S., Fedotovskaya O.I., Kholin A.M. Drug therapy for threatened premature birth. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2013; 5: 17-22. (in Russian)]
4. Савельева Г.М., Шалина Р.И., Курцер М.А., Клименко П.А., Сичинава Л.Г., Панина О.Б., Плеханова Е.Р., Выхристюк Ю.В., Лебедев Е.В. Преждевременные роды как важнейшая проблема современного акушерства. Акушерство и гинекология. 2012; 8-2: 4-10. [Savelyeva G.M., Shalina R.I., Kurtser M.A., Klimenko P.A., Sichinava L.G., Panina O.B., Plekhanova E.R., Vykhristyuk Yu.V., Lebedev E.V. Preterm birth as the most important problem of modern obstetrics. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2012; (8-2) 4-10. (in Russian)]
5. Сидельникова В.М. Преждевременные роды – современный взгляд на проблему. Вопросы практической педиатрии. 2006; 1(4): 55-6. [Sidelnikova V.M. Premature birth is a modern view of the problem. Voprosyi prakticheskoy pediatrii. 2006; 1 (4): 55-6. (in Russian)]
6. Башмакова Н.В. Сверхранние преждевременные роды: новые результаты. Status Praesens. 2014; 6: 13-9. [Bashmakova N.V. Supernumerary premature birth: new results. Status Praesens. 2014; 6: 13-9. (in Russian)]
7. Wood N., Marlow N., Costeloe K., Chir B., Gibson A., Wilkinson A. Neurologic and developmental disability after extremely preterm birth. EPICure Study Group. N. Engl. J. Med. 2000; 343(6): 378-84.
8. Радзинский В.Е., Галина Т.В., Кирбасова Н.П., Гондаренко А.С. Преждевременные роды: есть ли перспективы? Акушерство и гинекология. 2015; 2: 99-103. [Radzinsky V.E., Galina T.V., Kirbasova N.P., Gondarenko A.S. Premature delivery: Are there promises? Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2015; (2) 99-103. (in Russian)]
9. van Vliet E.O.G., Nijman T.A.J., Schuit E., Heida K.Y., Opmeer B.C., Kok M. et al. Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): a multicentre, randomised controlled trial. Lancet. 2016; 387(10033): 2117-24. doi: 10.1016/S0140-6736(16)00548-1.
10. Haram K., Mortensen J.H., Morrison J.C. Tocolysis for acute preterm labor: does anything work. J. Matern. Fetal Neonatal Med. 2015; 28(4): 371-8. doi: 10.3109/14767058.2014.918095.
11. Jorgensen J.S., Weile L.K., Lamont R.F. Preterm labor: current tocolytic options for the treatment of preterm labor. Expert Opin. Pharmacother. 2014; 15(5): 585-8.
12. Lamont R.F., Kam K.Y.R. Atosiban as a tocolytics for the treatment of spontaneous preterm labor. Expert Rev. Obstet. Gynecol. 2008; 3(2): 163-74.
13. Manuck T.A., Herrera C.A., Korgenski E.K., Jackson M., Stoddard G.J., Porter T.F., Varner M.W. Tocolysis for women with early spontaneous preterm labor and advanced cervical dilation. Obstet. Gynecol. 2015; 126(5): 954-61. doi: 10.1097/AOG.0000000000001095.
14. Saleh S.S., Al-Ramahi M.Q., Al Kazaleh F.A. Atosiban and nifedipine in the suppression of pre-term labour: a comparative study. J. Obstet. Gynaecol. 2013; 33(1): 43-5. doi: 10.3109/01443615.2012.721822.
15. Wex J., Abou-Setta A.M., Clerici G., Di Renzo G.C. Atosiban versus betamimetics in the treatment of preterm labour in Italy: clinical and economic importance of side-effects. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011; 157(2): 128-35. doi: 10.1016/j.ejogrb. 2011.04.009.
16. Баев О.Р., Козлова О.А., Тысячный О.В., Усова Е.А. Применение блокатора окситоциновых рецепторов – атозибана для торможения спонтанной родовой деятельности. Акушерство и гинекология. 2015; 1: 5-11. [Baev O.R., Kozlova O.A., Tysyachnyi O.V., Usova E.A. Use of the oxytocin receptor blocking agent atosiban to suppress spontaneous labor. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2015; (1) 5-11. (in Russian)]
17. Helmer H., Brunbauer M., Rohrmeister K. Exploring the role of Tractocile in everyday clinical practice. BJOG. 2003; 110(Suppl. 20): 113-5.
18. Xu Y.J., Ran L.M., Zhai S.S., Luo X.H., Zhang Y.Y., Zhou Z.Y. et al. Evaluation of efficacy of atosiban in pregnant women with threatened preterm labor assotiated with assisted reproductive technology. Eur. Rev. Med. Pharmacol. Sci. 2016; 20(9): 1881-7.
19. Husslein P., Roura L., Dudenhausen J., Helmer H., Frydman R., Rizzo N., Schneider D. on behalf of the TREASURE study group. Clinical practice evaluation of atosiban in preterm labour management in six European countries. BJOG. 2006; 113(Suppl. 3): 105-10.
20. Курцер М.А., Кутакова Ю.Ю., Черепнина А.Л., Борец М.В., Курбатская О.Н. Опыт применения трактоцила (атозибан) при лечении беременных с угрозой преждевременных родов. Российский вестник акушера-гинеколога. 2014; 14(3): 47-9. [Kurtser M.A., Kutakova Yu.Yu., Cherepnina A.L., Borets M.V., Kurbatskaya O.N. The experience of using tracotocil (atosiban) in the treatment of pregnant women with the threat of premature birth. Rossiyskiy vestnik akushera-ginekologa. 2014; 14 (3): 47-9. (in Russian)]
21. Фаткуллин И.Ф., Фаткуллин Ф.И., Мунавирова А.А., Исламова Л.Х., Ахметгалиев А.Р., Шайхетдинова А.Т. Опыт применения блокатора окситоциновых рецепторов при начавшихся преждевременных родах. Акушерство и гинекология. 2016; 6: 73-7. http://dx.doi.org/10.18565/aig.2016.6.73-77 [Fatkullin I.F., Fatkullin F.I., Munavirova A.A., Islamova L.Kh., Akhmetgaliev A.R., Shaikhetdinova A.T. Experience with oxytocin receptor antagonist for incipient preterm labor. Akusherstvo i ginekologiya/Obstetrics and Gynecology. 2016; (6): 73-77. (in Russian) http://dx.doi.org/10.18565/aig.2016.6.73-77]
Received 02.11.2016
Accepted 11.11.2016
About the Authors
Baev Oleg Radomirovich, MD, professor, head of the maternity department, Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. E-mail: o_baev@oparina4.ruVasilchenko Oksana Nikolayevna, Candidate of Medical Sciences, Senior Researcher Maternity department, Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. E-mail: o_vasilchenko@oparina4.ru
Karapetyan Anna Ovikovna, Post-graduate of the maternity department, Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia.
117997, Russia, Moscow, Ac. Oparina str. 4. E-mail: a_karapetyan@oparina4.ru
Tetruashvili Nana Kartlosovna, MD, head of the 2 department obstetric pathology of pregnancy, Research Center of Obstetrics, Gynecology and Perinatology,
Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. E-mail: n_tetruashvili@oparina4.ru
Khodzayeva Zulfiya Sagdullaevna, MD, professor, leading researcher, Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia.
117997, Russia, Moscow, Ac. Oparina str. 4. E-mail: z_khodzhaeva@oparina4.ru
For citations: Baev O.R., Vasilchenko O.N., Karapetyan A.O., Tetruashvili N.K.,
Khodzhaeva Z.S. Efficacy of atosiban for threatened preterm birth.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (9): 96-101. (in Russian)
http://dx.doi.org/10.18565/aig.2017.9.96-101
Similar Articles
